L'Usine Digitale Merck Serono mise sur les médicaments connectés L'Usine Digitale Pour se différencier de ses concurrents dans les traitements de maladies chroniques, le laboratoire pharmaceutique allemand Merck Serono tente des "solutions...
"This survey is an attempt to determine the issues involving transparency and conflicts of interest that may arise if and when pharma companies pay individual POLs to help manage their engagement with patients online. What best practices should govern pharma's collaboration with POLs? Should the industry develop guidelines for their interactions with POLs via social networks (eg, develop a "Patient Opinion Leader Transparency Policy")?"
I heard that a number of participants at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco were "baffled" by LAP-BAND's social media campaign. LAP-BAND, marketed by Apollo Endosurgery, is a medical device that is inserted surgically around the stomach to reduce its capacity and thus aid in weight loss.
LAP-BAND has a limited indication: "for weight reduction for patients with obesity, with a Body Mass Index (BMI) of at least 40 kg/m2 or a BMI of at least 30 kg/m2 with one or more obesity-related comorbid conditions." It also has a number of possible adverse events such as "band slippage, erosion and deflation, reflux, obstruction of the stomach, dilation of the esophagus, infection, or nausea and vomiting may occur."
It seems that several tweets posted by the @LAPBAND Twitter account violate recent FDA "Guidance for Industry Internet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices" (here).
First, here's what the @LAPBAND Twitter page looks like:
Click on image for an enlarged vie.
You can SEE - but you probably can't READ - the Important Safety Information (ISI) in the upper right corner. Technically, I suppose this satisfies FDA requirements that ISI must accompany branded Rx and medical device ads that mention benefits of the product.
But it's the tweets themselves that FDA should be looking out. Let me explain why.
If you scroll down the @LAPBAND Twitter page, you find tweets such as the following:
These tweets mention the product brand name ("#LAPBAND") and the indication ("lost 260 lbs." and "#weightloss"). Should these tweets that also include the minimal ISI as per FDA's guidance document mentioned above? The ISI is at the top of the page where these tweets are displayed, but you have to scroll up to see it.
NOTE: Since the Twitter handle is the name of the product (LAP-BAND), the brand name is actually part of every tweet. Thus even tweets that don't include LAPBAND or LAP-BAND in the body of the tweet, must include safety information if it mentions weight loss.
Is there a "One Scroll Away Rule?"
So, technically you have the ISI "one scroll away" and that's probably OK with the FDA -- there's precedent: many Rx drug websites have ISI at the bottom of the page and you have to scroll down to see it. So far, FDA has not sent any letters about that, so the "One Scroll Away Rule" is received precedent.
BUT... Twitter is different because most people probably do not view these tweets directly on the @LAPBAND Twitter page. Like me, many consumers view tweets on their mobile phones using the Twitter app, which does not display the whole page, or via Tweetdeck. Here's how the tweet above looks on Tweetdeck (also on iPhone):
No ISI. Not any safety information at all! Clearly FDA should be looking at the @LAPBAND social media campaign and writing Apollo Endosurgery aWarning Letter.
BTW, you really have to scroll down a LOT on the www.lapband.com site to see the ISI. Just sayin'
Santé : L’Usine Nouvelle - 2014 a été une année difficile pour la pharmacie, toujours en récession. Etes-vous plus optimiste pour... Articles liés Exclusif, Santé, Pharmacie, Pharmacie / Biotechnologies - L'information de l'industrie
New patient engagement trends from TechnologyAdvice Research reveals digital engagement is a growing factor in how patients choose healthcare providers.
Quality of care has long been a primary factor in choosing a healthcare provider, but convenience and communication are also becoming key considerations for patients. Still, many physicians do not appear to be offering the digital engagement services that can meet those demands.
According to a new nationwide survey conducted by TechnologyAdvice Research, a majority of patients (60.8 percent) said digital services like online appointment scheduling and online bill pay are either “important” or “somewhat important” when choosing a physician. However, when asked what services their current physician provides, less than one-third of patients indicated they have access to either online bill pay, online appointment scheduling, or the ability to view test results and diagnoses online, which are the top three services that patients report wanting the most.
“Primary care physicians are reporting some of the highest rates of EHR adoption to comply with government regulations and to receive incentives from Meaningful Use, but a significantly lower number of patients claim to have access to these patient portal services,” said TechnologyAdvice Managing Editor Cameron Graham, who authored the survey. “The issue here may not be implementation of digital services, but instead a lack of patient awareness. If physicians are offering these in-demand digital services, a more proactive approach to promoting them is needed and could create an advantage in attracting and retaining patients.”
- If providers wish to gain an upper edge in attracting new patients (especially younger ones), and in retaining their existing patients, they should invest in a fully featured patient portal system. For many primary care physicians this should not be difficult. Most comprehensive EHRs include patient portal features, and dedicated patient portal vendors are making strides in integrating with third-party systems. In particular, prioritizing systems with intuitive online appointment scheduling, online bill pay functionality, and online test results could provide a significant draw for new patients.
- For practices that already have patient portal systems, they should dedicate resources to making sure their patient populations are informed of the existence of such services. They should also consider prominently featuring these services in their advertising and on their websites. When orienting new patients to their practice, providers need to have a plan for walking patients through the initial portal set-up requirements and making sure they understand the features available to them.
-For particularly tech-savvy practices, a dedicated smartphone app could help set them apart, and attract younger individuals.
Lupus study and research community forms just one part of their collaboration. Following on hot on the heels of its Parkinson's disease collbaoration with Genentech, 23andMe will give Pfizer access to its research and analysis services.
Les exigences en matière de sécurité du médicament se durcissent mais se heurtent à de nombreux obstacles, principalement techniques, ont pointé les Académies de Médecine, de Pharmacie et des Sciences lors d'une séance commune. Les différents intervenants ont présenté des pistes d'amélioration.
"POST SUMMARY: Believe it or not patients do want to hear from pharma brands via digital channels, but patient expectations have to be in line with product websites or else they are turning elsewhere to make health care decisions."
The effect of social technologies in customer-facing processes is already significant. Our survey finds that while overall adoption of these tools has plateaued, companies can do more to measure and then capture social’s benefits. A McKinsey & Company article.
Two major challenges why Indian pharma isn't doing great on Digital Marketing, in the backdrop of #DigiSights 2015 - Indian Pharma in Digital marketing.
1. Madness for digital gimmicks
Yesterday’s Facebook page is today’s mobile app – a common problem of the digital and social media industry in the country. Three years back every brand wanted to be on Facebook with a million fans and today the same madness has evolved to having a mobile app. Nobody is talking about “Why” do we need an app or the need to be present on a network. Does that solve the customer problem? Does it reduce the ever-growing divide of doctor and patient?
2. Lack of trust for Pharma
“Nobody trusts our Pharma industry, why would today’s evolved world do?” were the opening lines Salil Kallianpur from GSK-Global. Blunt but the accepted truth by everyone present.
Today the customer is well equipped; gone are the days when Pharma industry could take them for a ride. Unless they adopt digital as a culture and start taking data seriously, Pharma marketing in India would be handicapped.